CN112831512A - 一种枣果实中腺苷酸环化酶的基因编码序列 - Google Patents
一种枣果实中腺苷酸环化酶的基因编码序列 Download PDFInfo
- Publication number
- CN112831512A CN112831512A CN202110255984.8A CN202110255984A CN112831512A CN 112831512 A CN112831512 A CN 112831512A CN 202110255984 A CN202110255984 A CN 202110255984A CN 112831512 A CN112831512 A CN 112831512A
- Authority
- CN
- China
- Prior art keywords
- adenylate cyclase
- gene
- coding sequence
- gene coding
- jujube fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 108060000200 adenylate cyclase Proteins 0.000 title claims abstract description 31
- 102000030621 adenylate cyclase Human genes 0.000 title claims abstract description 26
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 17
- 108091026890 Coding region Proteins 0.000 title claims abstract description 12
- 240000008866 Ziziphus nummularia Species 0.000 title 1
- 241001247821 Ziziphus Species 0.000 claims abstract description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 3
- 238000011160 research Methods 0.000 claims description 3
- 101150095244 ac gene Proteins 0.000 claims description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000126002 Ziziphus vulgaris Species 0.000 description 3
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 101150101102 cyaA gene Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YBPWNFMPWVRSOD-QDEZUTFSSA-N 5-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-hydroxynonane-4,6-dione Chemical compound C(CCC)(=O)C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC1=2)O)O)(O)C(CCC)=O YBPWNFMPWVRSOD-QDEZUTFSSA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000269335 Ambystoma laterale x Ambystoma jeffersonianum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 101100276209 Rhizobium meliloti (strain 1021) cya1 gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 101150084863 cya gene Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/32—Nucleotides having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明公开了一种枣果实中腺苷酸环化酶的基因编码序列，编码腺苷酸环化酶(AC)的ZjAC4基因如SEQ ID No.1所示的DNA序列。本发明采用上述的一种枣果实中腺苷酸环化酶的基因编码序列，以高效合成cAMP，具有重要的应用价值。
Description
技术领域
本发明涉及腺苷酸环化酶技术领域，尤其是涉及一种枣果实中腺苷酸环化酶的基因编码序列。
背景技术
环磷酸腺苷(cyclic adenosine monophosphate，简称cAMP)是人体内广泛存在的一种具有重要生理活性的物质，其作为细胞内的第二信使，对糖代谢、脂肪代谢、核酸合成、蛋白质合成等发挥着重要的调节作用。临床上cAMP用于治疗慢性充血性心力衰竭、肺心病、心肌梗死、心肌炎及心源性休克；对改善风湿性心脏病的心悸、气急、胸闷等症状有一定的作用；可提高急性白血病结合化疗的疗效，亦可用于急性白血病的诱导缓解；此外，对老年慢性支气管炎、各种肝炎和银屑病也有一定疗效。cAMP也可作为药物中间体制备二丁酰环磷酸腺苷和环磷酸腺苷葡甲胺，提高脂溶性，从而发挥更有效的生理及药理作用。cAMP亦可用于畜禽饲料添加剂，在离体条件下模拟生长激素的作用，促进畜禽生长，增加优质禽产品产量。
其中，环磷酸腺苷(cAMP)合成的关键酶为腺苷酸环化酶(AC)，AC能够催化ATP形成cAMP和焦磷酸(PPi)。AC类型多样，已知的AC包括AC-Ⅰ、Ⅱ、Ⅲ、Ⅳ、Ⅴ和Ⅵ六大类，分布于原核生物、原生生物、真菌和动物中。但是，植物cAMP和AC基因研究较晚，目前仅有9个植物AC基因被报道，且这9个基因均来自于草本植物，木本植物中尚无报道，这与绝大多数植物中cAMP含量极其低不无关系，不过，枣果实中cAMP含量极高，说明枣中极有可能包含植物中合成cAMP的关键酶及基因。
发明内容
本发明的目的是提供一种枣果实中腺苷酸环化酶的基因编码序列，可以高效合成cAMP，具有重要的应用价值。
为实现上述目的，本发明提供了一种枣果实中腺苷酸环化酶的基因编码序列，编码腺苷酸环化酶(AC)的ZjAC4基因如SEQ ID No.1所示的DNA序列。
优选的，ZjAC4基因序列在AC基因研究中的应用。
因此，本发明采用上述一种枣果实中腺苷酸环化酶的基因编码序列，以高效合成cAMP，具有重要的应用价值。
下面通过附图和实施例，对本发明的技术方案做进一步的详细描述。
附图说明
图1是蛋白催化试验中的酶催化效率示意图；
图2是枣树在体瞬时表达试验中cAMP含量变化示意图；
图3是枣树在体瞬时表达试验中ZjAC4表达量变化示意图；
图4是大肠杆菌缺陷型互补试验结果图。
具体实施方式
以下通过附图和实施例对本发明的技术方案作进一步说明。
一、ZjAC4基因的获得
(1)根据NCBI数据库中已有报道的其它植物中的ACs基因的保守核苷酸序列，设计引物(正向：5’-ATGGAAGTCGAAGTCAAGCT-3’；反向：5’-GATCGAAAAACNGCAAATTTNG-3’)；
(2)提取冬枣果实RNA，后反转录为cDNA作PCR扩增模板，进行PCR扩增；
PCR扩增程序：94℃，4min；(94℃，40s；55℃，45s；72℃，1.5min)35个循环；72℃，10min。
PCR产物经琼脂糖凝胶电泳观察扩增结果，并对候选目的条带进行琼脂糖凝胶回收，回收产物连接入pMDTM19-T克隆载体进行测序，得到ZjAC4序列，作为候选枣腺苷酸环化酶基因，进行功能验证。
二、功能验证
(1)大肠杆菌缺陷型互补试验
大肠杆菌cyaA缺陷型SP850菌株缺少腺苷酸环化酶(AC)基因，将带有ZjAC4基因的pET-15b重组质粒热机转化入SP850后，涂布与氨苄和卡纳抗生素培养皿，挑单克隆培养至OD600为0.5，后诱导表达培养4h，于麦康凯培养基划线培养，观察。结果发现，带有重组质粒的SP850缺陷型菌株和野生型大肠杆菌菌株的菌落颜色均为红色，而SP850缺陷型菌株在麦康凯培养基中显色为白色，说明ZjAC4基因弥补了SP850菌株中缺少的cyaA基因，发挥了腺苷酸环化酶基因的功能。
(2)蛋白质体外催化试验
将带有ZjAC4基因的pET-15b重组载体转入大肠杆菌BL21菌株，37℃，200rpm培养，后进行蛋白提取纯化，所得蛋白用于酶催化活性检测，结果如图1。结果发现，锰离子作为辅酶离子时，催化体系中产生了大量cAMP，说明ZjAC4蛋白能够有高效的AC功能，催化ATP形成cAMP。
酶催化活性检测条件如下。
催化体系：50mM TRIS-HCl(pH 7.5)，0.5mM ATP和20mM辅酶金属离子，催化条件为30℃，20min。
催化完成后使用高效液相色谱(HPLC)，检测催化体系中cAMP含量，从而确定酶催化活性及效率。
检测条件如下：色谱柱为Agilent Eclipse XDB-C18(4.6×250mm,5μm)，柱温30℃，流动相为甲醇：20mmol磷酸二氢钾体积比10：90，检测波长254nm，进样体积20μm，流速0.8ml/min。
(3)枣树载体瞬时表达试验
将ZjAC4基因克隆到pCG3301植物过表达载体，并通过热激转化法转入农杆菌GV3101中并涂布于含利福平(50μg/ml)和卡那霉素(50μg/ml)的LB固体培养基中，后挑单克隆菌落于含同样抗生素的LB液体培养基中28℃，200rpm培养至菌液OD600＝0.6。
收集菌体，重悬于10mM MES、10mM MgCl2和200mM乙酰丁香酮，pH6.0的注射侵染液中，取2mL注射于白熟期的冬枣果实中，注射后24h和72h取冬枣果实，检测ZjAC4基因的表达量及cAMP的含量，结果如图2-3所示。
结果发现，试验组(即注射重组后pCG3301)相较于空载组(pCG3301)及空白对照组，ZjAC4的表达量显著提升，同时cAMP的含量也显著提升。
因此，本发明采用上述一种枣果实中腺苷酸环化酶的基因编码序列，以高效合成cAMP，具有重要的应用价值。
最后应说明的是：以上实施例仅用以说明本发明的技术方案而非对其进行限制，尽管参照较佳实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对本发明的技术方案进行修改或者等同替换，而这些修改或者等同替换亦不能使修改后的技术方案脱离本发明技术方案的精神和范围。
序列表
<110> 河北农业大学
<120> 一种枣果实中腺苷酸环化酶的基因编码序列
<141> 2021-03-09
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 624
<212> DNA
<213> 腺苷酸环化酶基因(AC)(2 Ambystoma laterale x Ambystomajeffersonianum)
<400> 1
atgcattcga tggggacgga attgaaactt cggatccgag actccacggc gcactgccgt 60
ctcaccaagc ttttgtctgc atttcacgtc gaaactcaac accaagagaa tttcttcttt 120
gacggtgcca acaacgagct gtcatcacaa caagtcgtgc tcttccttcg gttctacggt 180
gatgacaccc cacaatgctt catgtcactc aaagccaggg cagtcctgga cgagggtgtg 240
tacagggttg atgaggaggt ggaagagaat ttcgagccag cggttgggcg cgcctgtgtc 300
gcccaaccgg agaagctttc gtcggtggag tgtgggatat tgaagatgtt aaaggagaag 360
tttggggttc tcaactttgt ggggcttgga gggtttgtca atgtgaggga tgtgtacaag 420
tgggagggct tgaaattgga ggttgataag actctgtatg agtttgggac taatcatgag 480
attgagtatg aaactagtga tcctgaagga gtcaagaagg tgcttgagga gttcttgaag 540
gagaatggga tccaatactc ttactcgcag gcctcaaagt ttgaggtttt tcgatccaag 600
aaacttccac agtcagtgaa ttga 624
Claims (2)
1.一种枣果实中腺苷酸环化酶的基因编码序列，其特征在于：编码腺苷酸环化酶(AC)的ZjAC4基因如SEQ ID No.1所示的DNA序列。
2.根据权利要求1所述的一种枣果实中腺苷酸环化酶的基因编码序列，其特征在于：ZjAC4基因序列在AC基因研究中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110255984.8A CN112831512B (zh) | 2021-03-09 | 2021-03-09 | 一种枣果实中腺苷酸环化酶的基因编码序列 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110255984.8A CN112831512B (zh) | 2021-03-09 | 2021-03-09 | 一种枣果实中腺苷酸环化酶的基因编码序列 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112831512A true CN112831512A (zh) | 2021-05-25 |
| CN112831512B CN112831512B (zh) | 2021-10-26 |
Family
ID=75929982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110255984.8A Active CN112831512B (zh) | 2021-03-09 | 2021-03-09 | 一种枣果实中腺苷酸环化酶的基因编码序列 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112831512B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113604452A (zh) * | 2021-08-05 | 2021-11-05 | 河北农业大学 | 一种具有三磷酸腺苷隧道金属酶活性的ZjAC2编码基因序列 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161996A (zh) * | 2011-03-01 | 2011-08-24 | 洪洞县维民生生物科技有限公司 | 枣树抗坏血酸过氧化物酶基因及其在提高植物抗逆性中的应用 |
| CN112442511A (zh) * | 2021-01-04 | 2021-03-05 | 郑州大学 | 提高植物中腺苷酸环化酶表达活性与cAMP含量的方法 |
-
2021
- 2021-03-09 CN CN202110255984.8A patent/CN112831512B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161996A (zh) * | 2011-03-01 | 2011-08-24 | 洪洞县维民生生物科技有限公司 | 枣树抗坏血酸过氧化物酶基因及其在提高植物抗逆性中的应用 |
| CN112442511A (zh) * | 2021-01-04 | 2021-03-05 | 郑州大学 | 提高植物中腺苷酸环化酶表达活性与cAMP含量的方法 |
Non-Patent Citations (1)
| Title |
|---|
| NONE: "PREDICTED: Ziziphus jujuba triphosphate tunel metalloenzyme 3-like (LOC107415651),mRNA", 《GENBANK：XM_016024008》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113604452A (zh) * | 2021-08-05 | 2021-11-05 | 河北农业大学 | 一种具有三磷酸腺苷隧道金属酶活性的ZjAC2编码基因序列 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112831512B (zh) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7460179B2 (ja) | バイオレチノールを生産する微生物及びそれを用いたバイオレチノールの生産方法 | |
| US20200377557A1 (en) | Novel polypeptide and method of producing imp using the same | |
| CN108699547B (zh) | 一种高产cAMP的酵母菌株及其应用 | |
| EP3604514A1 (en) | Composition for tagatose production and method for tagatose production using same | |
| EP3674313A1 (en) | Novel polypeptide and method for producing imp using same | |
| EP3739044B1 (en) | Variant phosphoribosyl pyrophosphate amidotransferase and method for producing purine nucleotide by using same | |
| JPH07508406A (ja) | 変性されたスクロース濃度を有する植物の製造のためのｄｎａ配列およびプラスミド | |
| CN113774075B (zh) | 一株大肠杆菌基因工程菌及其发酵生产l-茶氨酸的方法 | |
| CN112831512B (zh) | 一种枣果实中腺苷酸环化酶的基因编码序列 | |
| CN114107143B (zh) | 一种生产5’-胞苷酸的方法 | |
| CN115851779A (zh) | 一种葡萄糖-6-磷酸脱氢酶基因RkZWF1及其应用 | |
| CN112553135B (zh) | 一种腺苷工程菌及其构建方法与应用 | |
| JP7072809B2 (ja) | 組換え微生物、その製造方法及び補酵素ｑ１０の生産における使用 | |
| CN114438102B (zh) | 一种草莓乙烯响应FaERF13基因及其在改变草莓果实成熟期的应用 | |
| CN110616205A (zh) | 一种用于黄酮糖苷合成制备的黄酮合酶 | |
| CN113151232B (zh) | 忽地笑1-氨基环丙烷-1-羧酸合成酶及其编码基因与应用 | |
| CN114517161A (zh) | 高产赤霉素ga3的基因工程菌、构建方法及应用 | |
| CN115896211A (zh) | 一种发酵生产胞磷胆碱的基因工程菌及应用 | |
| CN112725369B (zh) | 一种耐盐腺苷酸环化酶的基因、重组载体、重组菌及其应用 | |
| CN116286899B (zh) | 一种NADH激酶基因RkNADHK1及其应用 | |
| CN117802125B (zh) | 与作物种子胚乳合成茶氨酸相关的基因及应用 | |
| CN114717250B (zh) | 一种基于辅因子代谢工程策略改造蛹虫草菌提高虫草素产量的方法及应用 | |
| CN116286879A (zh) | 红曲米红曲霉重组pstf基因及其应用 | |
| KR101124617B1 (ko) | 신규 리포산 합성효소와 리포산 단백질 리가제를 이용한 알파-리포산의 생산방법 | |
| CN113604452A (zh) | 一种具有三磷酸腺苷隧道金属酶活性的ZjAC2编码基因序列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |